WebJun 5, 2024 · The safety profile of trastuzumab deruxtecan in this trial was similar to the established safety profile in patients with HER2-positive metastatic breast cancer. 23,24 … WebSep 30, 2024 · In the multicenter phase II DAISY trial, fam-trastuzumab deruxtecan-nxki (T-DXD) demonstrated efficacy in three cohorts of patients with HER2-overexpressing and HER2-low metastatic breast cancer, according to Maria Fernanda Mosele, MD, of Gustave Roussy, Villejuif, France, and colleagues. The results of the recent biomarker analyses, …
BC-DAISY: A Breast Cancer Decision Aid System
WebJan 24, 2024 · The investigators aim to test the activity of nivolumab monotherapy in primary breast tumors in a pre-operative window of opportunity trial. As the data of the investigators generated in the TONIC trial (metastatic TNBC) indicate that low dose doxorubicin may 'prime' the tumor microenvironment (TME) resulting in higher response rates on … WebMar 29, 2024 · In a phase 3 trial, patients with metastatic HER2-negative breast cancer and a germline BRCA mutation who received the PARP inhibitor exhibited a 2.8-month longer median progression-free survival ... t shirt freestyle
ESMO Congress OncologyPRO
WebAug 5, 2024 · Daisy and I: Our Journey Through Mast Cell Tumor Cancer: With Dallas Ryan, Daisy Dolittle Roberts. Daisy Roberts was diagnosed with Mast Cell Tumor … WebDec 30, 2024 · These new findings also suggest the importance of enrollment of non-white women in future clinical trials of HER2-low breast cancer. ... the phase 2 Daisy trial reported a clinically meaningful 30 ... WebJan 21, 2024 · The 2024 San Antonio Breast Cancer Symposium (SABCS) heralded promising clinical trial results for breast cancer patients—particularly for those living with metastatic disease. Findings at this year’s symposium showed that we’re making progress to expand and improve treatment options and tackle some of breast cancer’s biggest … t shirt frenchie